Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of pyrimidinecarboxylic acids and derivatives. It is an experimental drug with limited publicly available information regarding its mechanism of action, clinical indications, or development status. The only known target associated with this compound is Mitogen-activated protein kinase 1 (MAPK1), but the specific interaction (e.g., inhibition or activation), binding site, and functional effect are not detailed in available sources[1]. The compound has been cataloged in major chemical databases as an investigational agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [4-({5-(aminocarbonyl)-4-[(3-methylphenyl)amino]pyrimidin-2-yl}amino)phenyl]acetic acid.